The activation of the CSF1/CSF1R pathway could block the Th1-mediated immune response and other classical antitumor immune effector pathways, whereas blocking the CSF1/CSF1R pathway could prevent TAM trafficking and enhance the efficacy of immune checkpoint-based therapies in HCC. The gene discussed is CSF1R; the disease is hepatocellular carcinoma.